Table 4 Summary of ongoing studies to evaluate safety profile and efficacy of PEGPH20 in multiple cancers
Intervention | Phase | Targeting Cancers | Primary Outcome Measures | Clinical Trial Identifier |
|---|---|---|---|---|
PEGPH20 + pembrolizumab | II | Metastatic pancreatic cancer | Progression free survival (PFS) | NCT03634332 |
PEGPH20 + gemcitabine + RT | II | Localized, unresectable pancreatic cancer | Number of participants with adverse events | NCT02910882 |
PEGPH20 + gemcitabine + nab-paclitaxel + rivaroxaban | N/A | Advanced pancreatic cancer | Rate of symptomatic thromboembolic events | NCT02921022 |
PEGPH20 + gemcitabine + nab paclitaxel vs Placebo + gemcitabine + nab-paclitaxel | III | Stage IV previously untreated pancreatic cancer | PFS & Overall Survival | NCT02715804 |
PEGPH20 + gemcitabine + nab-paclitaxel vs PEGPH20 alone | II | pancreatic cancer | Pathologic complete response, clinically relevant pancreatic fistula | NCT02487277 |
PEGPH20 + avelumab | I | Chemotherapy resistant pancreatic cancer | Overall response rate & safety profile | NCT03481920 |
PEGPH20 + pembrolizumab | Ib | Relapsed/ refractory non-small cell lung cancer & gastric cancer | Overall response rate | NCT02563548 |
PEGPH20 + eribulin mesylate vs eribulin mesylate alone | Ib/II | Metastatic breast cancer | Recommended phase II dose, overall response rate | NCT02753595 |
PEGPH20 + Cisplatin (CIS) + Gemcitabine (GEM) vs PEGPH20 + Atezolizumab + CIS + GEM vs CIS + GEM | I | Cholangiocarcinoma & Gallbladder cancer | Treatment adverse events and objective response rate | NCT03267940 |